Cytosorbents Corp
CTSO
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.91M
Close$
$2.35
23.1% downside
Current Fair Value
23.1% downsideOvervalued by 23.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.91 Million |
|---|---|
| Enterprise Value | $33.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.6 |
| Beta | 1.37 |
| Outstanding Shares | 3,140,335 |
Return
| Return on Equity | 2425.17% |
|---|---|
| Return on Assets | -47.98% |
| Return on Invested Capital | -96.91% |
Valuation & Multiples
| P/E Ratio | -0.66 |
|---|---|
| PEG | 0.2 |
| Price to Sales | 0.28 |
| Price to Book Ratio | -3.06 |
| Enterprise Value to Revenue | 0.91 |
| Enterprise Value to EBIT | -2.5 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.78 |
| Debt to Equity | -35.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$9.80 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$10.10 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 14,400▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 25.69%▼ 0.56% |
|---|---|
| Total Invested | $6.04M▼ 35.22% |
| Investors Holding | 51▲ 1.00% |
ESG Score
No data
About Cytosorbents Corp
CEO: Phillip Chan